[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acne-prone-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acne-prone-skin":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100659429","observational-assessment-of-skin-appearance-changes-during-prx-s-cosmetic-treatment-in-participants-with-acne-prone-skin-100659429",false,"NCT07866131","Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin","Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone Skin: A Multicenter Pilot Cohort Pre-Post Study","Inclusion Criteria:\n\n* Age 18 years or older at the time of informed consent.\n* Presence of acne-prone skin characteristics defined as an IGA score of 1 (almost clear) to 3 (moderate) at baseline (T0).\n* Willing and able to commit to 5 in-office treatment sessions at approximately 2-week intervals over approximately 8 weeks, plus one follow-up visit at Week 10.\n* Willing to discontinue all current skincare products and adhere exclusively to the WiQo standardized home care regimen throughout the study period. The participant's current skincare regimen must be, in the investigator's judgment, safe to discontinue on the day of the first treatment session without requiring a prior washout period.\n* Able to understand and willing to sign the informed consent form prior to any study procedure.\n* In general good health as determined by medical history and investigator judgment.\n* Ability to read and understand English at a level sufficient to provide written informed consent and complete all study questionnaires independently.\n\nExclusion Criteria:\n\n* IGA score of 0 (clear) or 4 (severe) at baseline.\n* Active skin infection, open wounds, or acute inflammatory dermatological conditions in the facial treatment area at the time of enrollment.\n* History of hypersensitivity or known allergy to any component of the PRX S formulation or the WiQo home care products.\n* Use of systemic retinoids within 6 months prior to enrollment.\n* Use of systemic antibiotics for acne within 4 weeks prior to enrollment.\n* Ongoing use of topical prescription acne medications (retinoids, topical antibiotics, dapsone) that the participant is unwilling or unable to discontinue.\n* Pregnancy, breastfeeding, or planned pregnancy during the study period. Pregnancy status is determined by participant self-report at screening and confirmed through the signed Informed Consent Form, in which the participant acknowledges that pregnancy constitutes a contraindication to the study treatment.\n* Prior cosmetic or aesthetic treatment of the face (chemical peel, laser, microneedling, injectables) within 4 weeks prior to enrollment, or prior treatment of the chest or back within 4 weeks prior to enrollment that, in the investigator's judgment, could confound GAGS assessments.\n* Any active medical condition that, in the investigator's judgment, could confound study assessments or place the participant at undue risk.\n* Participation in another interventional clinical study within 30 days prior to enrollment.\n* Inability or unwillingness to comply with study procedures and follow-up requirements.",true,"ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pilot cohort study evaluates changes in skin surface appearance in adult participants with acne-prone skin during and following a standardized five-session course of PRX S (WiQo SpA), a topical cosmetic product designed for oily and acne-prone skin.\n\nThe study asks whether a standardized in-office PRX S treatment cycle - five sessions administered at two-week intervals and complemented by a prescribed home care regimen - is associated with observable changes in objective skin surface parameters (pore appearance, texture, spots, redness, porphyrins), clinician-rated acne severity (IGA, GAGS), and participant-reported skin-related quality of life (QoL-RA) in adults with acne-prone skin.\n\nUsing a single-group, pre-post observational design across two U.S. sites (Leawood, KS and Tulsa, OK), 30 participants will undergo VISIA complexion analysis and clinical assessments at baseline (T0), mid-cycle (T1, Week 6), and end of follow-up (T2, Week 10). No single primary endpoint is designated; all analyses are explicitly exploratory.",[27,28],"Acne-prone Skin","Skin Disease",[30,31,32,33,34,35],"acne-prone skin","skin condition","cosmetics","pore refinement","quantitative evaluation","quality of life","RECRUITING","2026-10-06",{"date":39,"type":40},"2026-10-08","ACTUAL",{"date":42,"type":40},"2026-09-21",{"date":44,"type":21},"2026-12",{"name":46,"class":47},"WiQo S.p.A.","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100658311","dermal-and-ophthalmological-acceptability-and-comedogenicity-assessment-of-a-cosmetic-product-100658311","NCT07848555","Dermal and Ophthalmological Acceptability and Comedogenicity Assessment of a Cosmetic Product","Clinical Evaluation of Dermal and Ophthalmological Acceptability and Comedogenic and Acnegenic Potential of a Cosmetic Product","Inclusion Criteria:\n\n* Male and female participants aged 18 to 45 years.\n* Participants with oily, acne-prone skin.\n* Willingness to comply with all study procedures and attend the study site on the scheduled dates and times for assessments.\n* Ability to understand the study requirements, provide written informed consent, and sign the Informed Consent Form (ICF).\n* Normal ophthalmological examination, including slit-lamp evaluation.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study, when applicable.\n* Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening.\n* Skin conditions or marks in the test area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn.\n* History of atopy or allergic reactions to cosmetic products.\n* Active skin diseases and\u002For lesions (localized or widespread) in the assessment area.\n* Immunosuppression due to medication use or active disease.\n* Uncontrolled endocrine disorders.\n* Relevant medical history or current evidence of alcohol or substance abuse.\n* Known history of or suspected intolerance to products of the same category.\n* Intense sun exposure within 15 days prior to assessment.\n* Aesthetic or dermatological treatments within 4 weeks prior to assessment.\n* Any other condition that, in the investigator's opinion, may reasonably justify exclusion from the study.\n\nAdditional Ophthalmological Exclusion Criteria:\n\n* Presence of entropion, ectropion, hordeolum, conjunctivitis, uveitis, or other active ocular diseases at the time of screening.\n* Presence of corneal ulceration, blepharitis, meibomian gland dysfunction (meibomitis), pterygium, trichiasis, distichiasis, or other moderate to severe ocular conditions.\n* Initiation of contact lens use within 1 week prior to screening.\n* Use of ophthalmic products, including eye drops and\u002For ophthalmic ointments, within 3 weeks prior to screening.\n* Any other condition that, in the investigator's opinion, may reasonably justify exclusion from the study.","45 Years",{"count":57,"type":21},33,[24],"The goal of this clinical trial is to evaluate the dermatological and ophthalmological safety of a cosmetic product and to assess its comedogenic and acnegenic potential in participants with oily or acne-prone skin. The main questions it aims to answer are:\n\n* Does the investigational product demonstrate an absence of comedogenic potential under normal conditions of use?\n* Does the investigational product demonstrate an absence of acnegenic potential under normal conditions of use?\n* Does the investigational product demonstrate dermatological and ophthalmological acceptability?\n* Does the investigational product present a low risk of irritation or discomfort during the study period?\n\nParticipants will:\n\n* Apply the investigational cosmetic product to the face and body twice daily for 28 days.\n* Undergo dermatological evaluations to assess skin tolerability and identify any signs of irritation or adverse reactions.\n* Undergo ophthalmological evaluations to assess ocular tolerability.\n* Undergo clinical assessments to evaluate the comedogenic and acnegenic potential of the investigational product.\n\nThe study will enroll 33 male and female participants aged 18 to 45 years with oily or acne-prone skin. Participants will be followed for 28 days while using the investigational product according to the study protocol.",[61,62],"Oily Skin","Acne Prone Skin",[64,65,66,67,68,69,70,61,71,72],"Dermatological Safety","Ophthalmological Safety","Dermatological Acceptability","Ophthalmological Acceptability","Comedogenicity","Cosmetic Product","Acnegenicity","Acne-Prone Skin","Skin Tolerability","2026-09-23",{"date":75,"type":40},"2026-09-30",{"date":77,"type":40},"2026-09-08",{"date":79,"type":21},"2026-10-28",{"name":81,"class":47},"Brainfarma Industria Química e Farmacêutica S\u002FA",1]